Trump Loosens Restrictions on Psychedelic Drugs
Donald Trump,FDA,Joe Rogan,Robert F Kennedy Jr,Health,Public Health,Drugs,Psychedelics,Executive Orders
President Trump on Saturday signed an executive order seeking to hasten research into the therapeutic benefits of LSD, Ecstasy, psilocybin and other mind-altering drugs by ordering federal agencies to ease restrictions that have long limited the ability of scientists to study them.
The measure also provides $50 million for state-level research into ibogaine, a powerful psychedelic made from the root of a Central African shrub that has been drawing interest from researchers for its potential to treat opioid use disorder and other forms of substance abuse.
Related Coverage
AllSides Picks
Headline Roundup
Trump Says Military Escalation in Iran 'Unlikely,' Despite Earlier Mainstream Reporting
November 10th, 2026
Headline Roundup
Biased Outlets Slant Coverage of Trump's '60 Minutes' Interview
November 9th, 2026
Recommended Reading
When Trump Goes Out Like a Lion
Dan Schnur
November 9th, 2026
News
Tracking Trump’s Campaign Promises
AllSides Staff
November 7th, 2026